Abstract
An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 42-46 |
| Number of pages | 5 |
| Journal | Journal of Hospital Infection |
| Volume | 101 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2019 |
Keywords
- Healthcare worker
- High-risk exposure
- Middle East respiratory syndrome coronavirus
- Outbreak
- Post-exposure prophylaxis
- Pre-isolation pneumonia